Nektar Therapeutics

Stock Chart, Company Information, and Scan Results

$39.96(as of Sep 5, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Nektar Therapeutics Company Information, Fundamentals, and Technical Indicators

Stock Price$39.96
Ticker SymbolNKTR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees61
CountyUSA
Market Cap$543.0M
EBIDTA-137.2M
10-Day Moving Average29.30
P/E Ratio-4.15
20-Day Moving Average27.23
Forward P/E Ratio0.00
50-Day Moving Average25.58
Earnings per Share-8.64
200-Day Moving Average15.68
Profit Margin-372.20%
RSI78.20
Shares Outstanding19.0M
ATR2.14
52-Week High37.38
Volume3,494,936
52-Week Low6.48
Most Recent Support Level27.87
Book Value-24.2M
Most Recent Resistance Level30.45
P/B Ratio-20.94
Upper Keltner32.04
P/S Ratio6.76
Lower Keltner22.43
Debt-to-Equity Ratio32.04
Next Earnings DateUnknown
Cash Surplus-28.4M
Next Ex-Dividend DateUnknown

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Nektar Therapeutics In Our Stock Scanner

As of Sep 05, 2025
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.